Data protection Impressum

Oncology

From left to right: Prof. Han (Professor of Yonsei Cancer Center), Dr. Chun (CSO of Oncosoft), Prof. Dong Wook Kim (Clinical Professor, Yonsei Cancer Center), Laura Acosta (Swiss Embassy Representative), Prof. Ik Jae Lee (Director of Heavy Ion Therapy, Yonsei Cancer Center), Dr. Christina Vallgren (CEO of Terapet), Herve Duffour (Sales and Marketing director of Terapet), Prof. Jin Sung Kim (Chief Medical Physicist of Yonsei Cancer Center & CEO of Oncosoft).

Terapet enters partnership with Korean entities for its breakthrough cancer therapy device

18 October 2023

The third building of the site was inaugurated in the presence (from left to right) of Stéphane Coppey, the President of the City of Monthey, Christophe Darbellay, Head of the Department of Economy and Education, and Jean-Marc Tornare, President of BioArk.

BioArk Monthey’s third building signifies exponential growth in the life sciences sector

16 October 2023

Adiposs pioneers a new era in cancer patient care with a pivotal leap towards making ImageBAT a revolutionary tool in detecting hypermetabolism.

Adiposs completes the phase I clinical trial of its flagship product ImageBAT

11 October 2023

Lonza continues to fortify its position in ADC production, expanding collaboration and infrastructure to enhance its acclaimed Ibex Dedicate Biopark.

Lonza further extends its ADC manufacturing capabilities in Visp

9 October 2023

The Institute of Life Technologies of the HES-SO Valais/Wallis has forged a five-year collaboration with Debiopharm Research & Manufacturing to develop new targeted antibody fragment vectorization technologies.

HES-SO Valais-Wallis and Debiopharm partner up to battle cancer

4 October 2023

Top Stories Western Switzerland

Business environment

Top Stories from Western Switzerland (July-September 2023)

27 September 2023

The Vaud-based biotech start-up, ranking first in the TOP 100 Swiss Startup Award 2023, harnesses the dark genome to craft precise RNA therapies for disease-modifying cell states.

HAYA Therapeutics triumphs at the 13th TOP 100 Swiss Startup Award

11 September 2023

Backed by its parent company Nanobacterie's fourth-place in nanomedicine patent rankings by Marks and Clerk, AlphaOnco Swiss channels the synergy of Franco-Swiss collaboration to bring forth groundbreaking cancer treatments.

Nanomedicine pioneer Nanobacterie achieves remarkable patent ranking

23 August 2023

The canton of Bern, with its continual focus on advancing medicine through research, technology, and collaboration, stands as destination rich in opportunities for companies aiming to grow and innovate in the fields of medicine and life sciences.

Bern’s thriving ecosystem for life sciences innovation

9 August 2023

This discovery provides insight into the complex ecosystem of the tumor microenvironment and offers a new perspective on the treatment of cancer, particularly in the field of oncology.

UNIGE researchers lead breakthrough in understanding tumor growth

8 August 2023

1 2 3 4 5 6 7 8 9